Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $37 Price Target

Benzinga Newsdesk www.benzinga.com Negative 82.1%

Neg 82.1% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $37 price target.